{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:59:06Z","timestamp":1778860746401,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1685,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41379-018-0011-0","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T17:15:22Z","timestamp":1517850922000},"page":"881-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms"],"prefix":"10.1016","volume":"31","author":[{"given":"Qi","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata","family":"Yellapantula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maly","family":"Fenelus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Pichardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0011-0_bib1","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/onc.2013.152","article-title":"CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity","volume":"33","author":"Zucchini","year":"2014","journal-title":"Oncogene"},{"key":"10.1038\/s41379-018-0011-0_bib2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1091\/mbc.e05-10-0971","article-title":"CD99 acts as an oncosuppressor in osteosarcoma","volume":"17","author":"Manara","year":"2006","journal-title":"Mol Biol Cell"},{"key":"10.1038\/s41379-018-0011-0_bib3","doi-asserted-by":"crossref","unstructured":"Chung SS, Eng WS, Hu W et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci. Trans. Med. 2017;9.","DOI":"10.1126\/scitranslmed.aaj2025"},{"key":"10.1038\/s41379-018-0011-0_bib4","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2005-12-010827","article-title":"CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration","volume":"108","author":"Imbert","year":"2006","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0011-0_bib5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ajpath.2012.11.037","article-title":"Poliovirus receptor (CD155) regulates a step in transendothelial migration between PECAM and CD99","volume":"182","author":"Sullivan","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1038\/s41379-018-0011-0_bib6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1084\/jem.20150354","article-title":"Endothelial CD99 signals through soluble adenylyl cyclase and PKA to regulate leukocyte transendothelial migration","volume":"212","author":"Watson","year":"2015","journal-title":"J Exp Med"},{"key":"10.1038\/s41379-018-0011-0_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4049\/jimmunol.178.2.1136","article-title":"CD99 is a key mediator of the transendothelial migration of neutrophils","volume":"178","author":"Lou","year":"2007","journal-title":"J Immunol"},{"key":"10.1038\/s41379-018-0011-0_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/ni749","article-title":"CD99 plays a major role in the migration of monocytes through endothelial junctions","volume":"3","author":"Schenkel","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1038\/s41379-018-0011-0_bib9","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.4049\/jimmunol.159.5.2250","article-title":"CD99 (MIC2) regulates the LFA-1\/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion","volume":"159","author":"Hahn","year":"1997","journal-title":"J Immunol"},{"key":"10.1038\/s41379-018-0011-0_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.166.2.787","article-title":"CD99 regulates the transport of MHC class I molecules from the golgi complex to the cell surface","volume":"166","author":"Sohn","year":"2001","journal-title":"J Immunol"},{"key":"10.1038\/s41379-018-0011-0_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood.V83.2.415.415","article-title":"Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood","volume":"83","author":"Dworzak","year":"1994","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0011-0_bib12","first-page":"305","article-title":"Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations","volume":"26","author":"Dworzak","year":"1998","journal-title":"Exp Hematol"},{"key":"10.1038\/s41379-018-0011-0_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1365-2141.1999.01426.x","article-title":"CD99 (MIC2) expression in paediatric B-lineage leukaemia\/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis","volume":"105","author":"Dworzak","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1038\/s41379-018-0011-0_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.imlet.2015.10.015","article-title":"CD99 regulates CXCL12-induced chemotaxis of human plasma cells","volume":"168","author":"Gil","year":"2015","journal-title":"Immunol Lett"},{"key":"10.1038\/s41379-018-0011-0_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3346\/jkms.1999.14.6.600","article-title":"High CD99 expression in memory T and B cells in reactive lymph nodes","volume":"14","author":"Park","year":"1999","journal-title":"J Korean Med Sci"},{"key":"10.1038\/s41379-018-0011-0_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4132\/KoreanJPathol.2014.48.3.209","article-title":"Expression of CD99 in multiple myeloma: a clinicopathologic and immunohistochemical study of 170 cases","volume":"48","author":"Shin","year":"2014","journal-title":"Korean J Pathol"},{"key":"10.1038\/s41379-018-0011-0_bib17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1038\/s41379-018-0011-0_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1038\/s41379-018-0011-0_bib19","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0011-0_bib20","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.3324\/haematol.2015.128215","article-title":"Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen","volume":"101","author":"de Tute","year":"2016","journal-title":"Haematologica"},{"key":"10.1038\/s41379-018-0011-0_bib21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1038\/s41379-018-0011-0_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ajh.23831","article-title":"Flow cytometry detection of minimal residual disease in multiple myeloma: lessons learned at FDA-NCI roundtable symposium","volume":"89","author":"Landgren","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1038\/s41379-018-0011-0_bib23","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0011-0_bib24","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0011-0_bib25","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0011-0_bib26","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0011-0_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"10.1038\/s41379-018-0011-0_bib28","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1038\/s41379-018-0011-0_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cyto.b.21272","article-title":"Assessment of minimal residual disease in myeloma and the need for a consensus approach","volume":"90","author":"Rawstron","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1038\/s41379-018-0011-0_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ajcp\/aqw052","article-title":"Single-tube 10-fluorochrome analysis for efficient flow cytometric evaluation of minimal residual disease in plasma cell myeloma","volume":"14","author":"Royston","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1038\/s41379-018-0011-0_bib31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.13303","article-title":"Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process","volume":"169","author":"Rosado","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1038\/s41379-018-0011-0_bib32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1038\/s41379-018-0011-0_bib33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood.V124.21.722.722","article-title":"Interim analysis of the Mmrf commpass trial: identification of novel rearrangements potentially associated with disease initiation and progression","volume":"124","author":"Lonial","year":"2014","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0011-0_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.gde.2015.03.008","article-title":"Genomic heterogeneity in multiple myeloma","volume":"30","author":"Szalat","year":"2015","journal-title":"Curr Opin Genet Dev"},{"key":"10.1038\/s41379-018-0011-0_bib35","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13; q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1038\/s41379-018-0011-0_bib36","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2007-10-116590","article-title":"Validation of PDGFRbeta and c-Src tyrosine kinases as tumor\/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib","volume":"112","author":"Coluccia","year":"2008","journal-title":"Blood"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0011-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0011-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222014892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222014892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0011-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:50:27Z","timestamp":1760230227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222014892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0893395222014892"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0011-0","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0011-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}